Effects of antidyskinetic nicotine treatment on dopamine release in dorsal and ventral striatum

Show full item record



Permalink

http://hdl.handle.net/10138/299270

Citation

Leino , S , Koski , S K , Rannanpää , S & Salminen , O 2018 , ' Effects of antidyskinetic nicotine treatment on dopamine release in dorsal and ventral striatum ' , Neuroscience Letters , vol. 672 , pp. 40-45 . https://doi.org/10.1016/j.neulet.2018.02.042

Title: Effects of antidyskinetic nicotine treatment on dopamine release in dorsal and ventral striatum
Author: Leino, Sakari; Koski, Sini K.; Rannanpää, Saara; Salminen, Outi
Contributor: University of Helsinki, Regenerative pharmacology group
University of Helsinki, Faculty of Pharmacy
University of Helsinki, Faculty of Pharmacy
University of Helsinki, Faculty of Pharmacy
Date: 2018-04-13
Language: eng
Number of pages: 6
Belongs to series: Neuroscience Letters
ISSN: 0304-3940
URI: http://hdl.handle.net/10138/299270
Abstract: The treatment of Parkinson's disease is often complicated by levodopa-induced dyskinesia (LID), and antidyskinetic treatment options are currently sparse. Nicotinic acetylcholine receptors have been suggested as potential targets for treatment of LID, as nicotinic agonists have been reported to alleviate LID in animal models. We aimed at the first independent replication of an antidyskinetic effect by nicotine using a mouse model of LID, and at investigation of its mechanisms by studying the release of [H-3]dopamine from synaptosomes prepared from the dorsal and ventral striatum. Chronic nicotine treatment in drinking water inhibited the development of LID in mice lesioned unilaterally with 6-hydroxydopamine and treated chronically with levodopa and benserazide. The antidyskinetic nicotine treatment had no effect on [H-3]dopamine release mediated by alpha 4 beta 2* nicotinic receptors, but decreased alpha 6 beta 2*-mediated [H-3]dopamine release in the lesioned dorsal striatum and the ventral striatum. In addition, nicotine treatment restored [H-3]dopamine release in the lesioned ventral striatum to intact levels. The results support a role for nicotinic receptors as drug targets for treatment of LID, and suggest that striatal presynaptic alpha 6 beta 2* receptors are important mediators of nicotine's antidyskinetic effect.
Subject: Parkinson’s disease
levodopa
dyskinesia
nicotine
dopamine
317 Pharmacy
3112 Neurosciences
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0304394018301241_main.pdf 450.1Kb PDF View/Open
Leino_et_al_Neu ... on_040118_with_figures.pdf 518.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record